Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.

CEA is a French government-funded technological research organisation. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world. The CEA is the French Alternative Energies and Atomic Energy Commission (Commissariat à l'énergie atomique et aux énergies alternatives). It is a public body established in October 1945 by General de Gaulle. A leader in research, development and innovation, the CEA mission statement has two main objectives: To become the leading technological research organization in Europe and to ensure that the nuclear deterrent remains effective in the future. The CEA is active in four main areas: low-carbon energies, defense and security, information technologies and health technologies. In each of these fields, the CEA maintains a cross-disciplinary culture of engineers and researchers, building on the synergies between fundamental and technological research. The total CEA workforce consisted of 15 838 employees. Across the whole of the CEA (including both civilian and military research), there were 1556 PhD students and 293 post-docs. The CEA is based in ten research centers in France, each specializing in specific fields. The laboratories are located in the Paris region, the Rhône-Alpes, the Rhône valley, the Provence-Alpes-Côte d'Azur region, Aquitaine, Central France and Burgundy. The CEA benefits from the strong regional identities of these laboratories and the partnerships forged with other research centers, local authorities and universities.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Tokyo Metropolitan Institute of Medical Science is a Japanese private company. The firm operates as a research institute that develops medicine.

Toyama Chemical Co., Ltd. develops and supplies pharmaceutical products. It engages in information collection, clinical development of pharmaceuticals and distribution of healthcare products. The company was founded on November 15, 1936 and is headquartered in Tokyo, Japan.

Neurimmune Holding AG is a private company headquartered in Schlieren, Switzerland, with domestic subsidiaries, that manufactures pharmaceutical products. The firm was founded in 2006.\nThe company says this about itself: Neurimmune is a biopharmaceutical company translating human immune memory into transformative antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia, dementia with Lewy bodies and ATTR cardiomyopathy. Neurimmune discovered aducanumab, a human monoclonal antibody that removes amyloid beta from brains of patients with Alzheimer's disease, and licensed it to Biogen. With its RTM™ technology, Neurimmune also discovered the anti-miSOD1 antibody AP-101 for ALS and the anti-ATTR antibody NI006 for ATTR cardiomyopathy, programs being currently evaluated in clinical trials. Neurimmune has three additional antibody programs in preclinical development, and has recently expanded the spectrum of its treatment modalities by adding a small molecule program and programs involving vectorized expression of human antibody genes.

Acelot is a life science-based R&D company on advanced technology for drug discovery. This technology is made available as a web-based drug discovery platform, employed in-house for some drug-discovery projects in the central nervous system area. It allows the identification of latent pharmacophore information and can be used for rapid identification and optimization of drug development projects without clear target information or crystallography data.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2018, the company has one approved drug (see the Products section below).

Wave Life Sciences is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. We aspire to develop best-in-class medicines across multiple therapeutic modalities using PRISM™, our proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereo pure oligonucleotides. Driven by a resolute sense of urgency, we are targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. It also a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to groundbreaking treatments that will impact millions of lives. Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting. Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA.

Hangzhou Baishansheng Biotechnology Co., Ltd., established on 2013-03-21, Business scope includes chemical functional materials,biomaterials,Biological product,drug,potion,Reagent,Fine Chemicals,preventive products,Technical consultation in the field of blood products and other biotechnology products,technology transfer,Technical Service and Sales(Except for projects requiring pre-approval),Equipment,Office equipment rental(Demolition,Pack);Import and export of goods and technology(National law,Except for items prohibited by regulations,National law,Items that are restricted by laws and regulations can only be operated after obtaining a license);special food(Healthy food)Sales;All other legal items that do not need to be submitted for approval.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Vaccinex has developed an antibody discovery platform that enables efficient mammalian cell-based expression for expression of large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface envelope of a mammalian virus and the cell surface membrane of the infected cell. This allows them to combine the advantages of virus panning and cell sorting into one seamless selection process. This technology enables the rapid selection of 1010 antibody combinations and thus selection of high affinity leads with varied frameworks that recognize multiple epitopes. It is based in Rochester, New York.